Discovery Company acquires Molecular Modelling Expert

UK-based molecular modelling company Prosarix has been acquired by RxCelerate, one of the leading out-sourced drug discovery and development platforms in the United Kingdom. Originally founded in 2006, Prosarix has built a reputation as one of the leading exponents of molecular modelling, supporting both protein engineering and in silico drug design projects.

“The acquisition of Prosarix beautifully complements our existing drug discovery services, including our medicinal chemistry operations based at University of Warwick” said Dr Nigel Ramsden, Executive Vice President, Chemistry, at RxCelerate.

“Prosarix are already well-known to many of our clients” said Dr Jill Reckless, CEO of RxCelerate. “where they have demonstrated over and over again how their proprietary molecular modelling capabilities can discover better molecules than the competition. We are delighted to now have the unique expertise as part of RxCelerate Group.”

“We are very excited to have this opportunity to join a rapidly-expanding, global, quality biotech business, with a unique platform to delivering cutting-edge drug discovery and development on an out-sourced basis” said Dr Bill Hamilton, the current Chief Executive at Prosarix, which is currently based just outside Cambridge, UK.

RxCelerate operates a unique model, allowing clients to out-source complete drug discovery and development programs to a team of world-class drug developers obviating the need for internal expertise usually required when out-sourcing to contract research organisations. Founded in 2012, the company initially built its reputation on the quality of its preclinical models of human diseases, but rapidly expanded to offer a comprehensive, turnkey drug discovery and development solution.

“Following the acquisition of bioanalytical CRO Total Scientific and sector-focused back-office service provider The Cambridge Partnership during 2018, this new acquisition underlines our commitment to complete the jigsaw, so that our clients can access world-leading drug discovery capability under one roof” said Founder and Chairman, Dr David Grainger. “Jon Heal and the scientific team at Prosarix are talented modellers, with a proven track-record in molecular design.”